Informação sobre produto
- 1,3,5-Triazine-2,4-diamine, 3,6-dihydro-N2,N2,6-trimethyl-, (6R)-
- 1,3,5-Triazine-2,4-diamine,1,6-dihydro-N,N,6-trimethyl-, (6R)- (9CI)
- 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-N,N,6-trimethyl-, (6R)-
- R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]trazin-2-yl)dimethylamine
- R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]triazin-2-yl)dimethylamine
- Imeglimin
- EMD 387008
Imeglimin is a drug that acts as an antidiabetic agent by targeting energy metabolism. It has been shown to reduce the levels of blood glucose and improve insulin sensitivity in patients with type 2 diabetes. Imeglimin also reduces kidney fibrosis and improves mitochondrial membrane potential, redox potential, and ATP levels in liver cells. Imeglimin has significant interactions with other drugs that affect energy metabolism, such as metformin and phenformin. These drugs should be avoided in patients taking imeglimin to avoid toxic effects on the heart, liver, or kidneys. Imeglimin is metabolized by CYP2C19 into its active form imeglimine.
Propriedades químicas
Consulta técnica sobre: 3D-AGB35165 Imeglimin
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
